New directions in immunosuppression after heart transplantation

Nature Reviews Cardiology

Volumn 10, Issue 7, 2013, Pages 422-427

  Baran, David A ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

CARDIAC GRAFT REJECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS UROGRAPHY; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; VASCULAR DISEASE;

DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 84881091240     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.63     Document Type: Review

References (34)

1. Barnard, C. N. The operation. A human cardiac transplant: An interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S. Afr. Med. J. 41, 1271-1274 (1967).
2. Lawrence, S. V. Heart transplants: Blessing or boondoggle? Forum Med. 3, 441-445 (1980).
3. Caves, P. K. et al. Percutaneous transvenous endomyocardial biopsy. JAMA 225, 288-291 (1973).
4. Ridker, A. K. et al. The status of cardiac transplantation, 1975. Circulation 52, 531-539 (1975).
5. Leaf, A. Sounding board: The MGH trustees say no to heart transplants. N. Engl. J. Med. 302, 1087-1088 (1980).
6. Halloran, P. F., Lien, J., Aprile, M. & White, N. Preliminary results of a randomized comparison of cyclosporine and Minnesota Antilymphoblast Globulin. Transplant. Proc. 14, 627-630 (1982).
7. Devineni, R. et al. Cyclosporine in cardiac transplantation. Can. J. Surg. 27, 252-254 (1984).
8. Stehlik, J. et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J. Heart Lung Transplant. 31, 1052-1064 (2012).
9. Kobashigawa, J. et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66, 507-515 (1998).
10. Kobashigawa, J. A. et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial. Am. J. Transplant. 6, 993-997 (2006).
11. Eisen, H. J. et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349, 847-858 (2003).
12. Kobashigawa, J. A. et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J. Am. Coll. Cardiol. 45, 1532-1537 (2005).
13. Kobashigawa, J. A. et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1year report. Am. J. Transplant. 6, 1377-1386 (2006).
14. Grimm, M. et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-A large European trial. Am. J. Transplant. 6, 1387-1397 (2006).
15. Baran, D. A. Induction therapy in cardiac transplantation: When and why? Heart Fail. Clin. 3, 31-41 (2007).
16. Uber, P. A. & Mehra, M. R. Induction therapy in heart transplantation: Is there a role? J. Heart Lung Transplant. 26, 205-209 (2007).
17. Hershberger, R. E. et al. Daclizumab to prevent rejection after cardiac transplantation. N. Engl. J. Med. 352, 2705-2713 (2005).
18. Baran, D. A. et al. Tacrolimus in cardiac transplantation: Efficacy and safety of a novel dosing protocol. Transplantation 74, 1136-1141 (2002).
19. Baran, D. A. et al. Tacrolimus monotherapy in adult cardiac transplant recipients: Intermediate-term results. J. Heart Lung Transplant. 20, 59-70 (2001).
20. Lubitz, S. A. et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J. Heart Lung Transplant. 25, 699-706 (2006).
21. Baran, D. A. et al. Randomized trial of tacrolimus monotherapy: Tacrolimus in combination, tacrolimus alone compared (the TICTAC trial). J. Heart Lung Transplant. 26, 992-997 (2007).
22. Mehra, M. R. et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am. J. Cardiol. 75, 853-854 (1995).
23. Yamani, M. H. et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J. Heart Lung Transplant. 23, 272-276 (2004).
24. Baran, D. A. et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: The tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ. Heart Fail. 4, 129-137 (2011).
25. Dresske, B. et al. WOFIE stimulates regulatory T cells: A 2year follow-up of renal transplant recipients. Transplantation 81, 1549-1557 (2006).
26. Calne, R. Y. et al. Tolerance of porcine renal allografts induced by donor spleen cells and seven days' treatment with cyclosporine. Transplantation 57, 1433-1435 (1994).
27. Urschel, S. et al. ABO-incompatible heart transplantation in early childhood: An international multicenter study of clinical experiences and limits. J. Heart Lung Transplant. 32, 285-292 (2013).
28. Becker, T. et al. Patient outcomes in two steroidfree regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 86, 1689-1694 (2008).
29. Schneeberger, S. et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann. Surg. 257, 345-351 (2013).
30. US Department of Health & Human Sciences: FDA. Important drug information [online], http://www.fda.gov/downloads/Drugs/DrugSafety/ DrugShortages/UCM194907.pdf (2009).
31. Clinical Trials in Organ Transplantation. Approved studies [online], https://www.ctotstudies.org/Approved-Studies.htm (2013).
32. Shah, M. R., Starling, R. C., Schwartz Longacre, L. & Mehra, M. R. Heart transplantation research in the next decade-A goal to achieving evidence-based outcomes: National Heart, Lung, and Blood Institute Working Group. J. Am. Coll. Cardiol. 59, 1263-1269 (2012).
33. Eisen, H. J. et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. 24, 517-525 (2005).
34. Kobashigawa, J. et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant. Proc. 37, 1333-1339 (2005).